Esther Rajavelu serves as Executive at Spero Therapeutics, Inc., where they oversee executive responsibilities. Since joining the company, Esther Rajavelu has executed 6 insider transactions totaling $136.0K, demonstrating a bearish approach to their equity position. Their most recent transaction on Feb 2, 2026 involved receiving (via award) 498,000 shares valued at $0.
Esther Rajavelu currently holds 498,000 shares of Spero Therapeutics, Inc. (SPRO), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, Esther Rajavelu has been a net seller of SPRO stock. They have purchased $0 and sold $136.0K worth of shares.
Esther Rajavelu's most recent insider trade was on Feb 2, 2026, when they sold 498,000 shares at $0.00 per share.
Get notified when new Form 4 filings are submitted
| $2.20 |
| Discretionary |
| Feb 2, 2026 | SPRO | $0 | Award | 249,000 | $N/A | Discretionary |
| Nov 7, 2025 | SPRO | $95.4K | Sale | 40,270 | $2.37 | Discretionary |
| Feb 1, 2024 | SPRO | $0 | Award | 119,866 | $N/A | Discretionary |
| Nov 13, 2023 | SPRO | $0 | Award | 300,000 | $N/A | Discretionary |